Reported Earnings • Mar 27
Full year 2025 earnings released: EPS: CN¥0.01 (vs CN¥0.031 loss in FY 2024) Full year 2025 results: EPS: CN¥0.01 (up from CN¥0.031 loss in FY 2024). Revenue: CN¥646.1m (up 150% from FY 2024). Net income: CN¥57.1m (up CN¥185.1m from FY 2024). Profit margin: 8.8% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 26
Mabpharm Limited, Annual General Meeting, Jun 26, 2026 Mabpharm Limited, Annual General Meeting, Jun 26, 2026. New Risk • Mar 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Mar 12
Mabpharm Limited to Report Fiscal Year 2025 Results on Mar 26, 2026 Mabpharm Limited announced that they will report fiscal year 2025 results on Mar 26, 2026 Reported Earnings • Aug 31
First half 2025 earnings released: EPS: CN¥0.001 (vs CN¥0.024 loss in 1H 2024) First half 2025 results: EPS: CN¥0.001 (up from CN¥0.024 loss in 1H 2024). Revenue: CN¥274.2m (up 153% from 1H 2024). Net income: CN¥2.90m (up CN¥100.5m from 1H 2024). Profit margin: 1.1% (up from net loss in 1H 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Aug 15
Mabpharm Limited to Report First Half, 2025 Results on Aug 28, 2025 Mabpharm Limited announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • Aug 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥64m free cash flow). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Apr 25
Full year 2024 earnings released: CN¥0.031 loss per share (vs CN¥0.051 loss in FY 2023) Full year 2024 results: CN¥0.031 loss per share (improved from CN¥0.051 loss in FY 2023). Revenue: CN¥258.2m (up 196% from FY 2023). Net loss: CN¥127.9m (loss narrowed 39% from FY 2023). Products in clinical trials Phase I: 3 Phase III: 7 Post-clinical trial products Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 27
Full year 2024 earnings released: CN¥0.03 loss per share (vs CN¥0.051 loss in FY 2023) Full year 2024 results: CN¥0.03 loss per share (improved from CN¥0.051 loss in FY 2023). Revenue: CN¥258.2m (up 196% from FY 2023). Net loss: CN¥127.9m (loss narrowed 39% from FY 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 27
Mabpharm Limited, Annual General Meeting, Jun 18, 2025 Mabpharm Limited, Annual General Meeting, Jun 18, 2025. Announcement • Mar 13
Mabpharm Limited to Report Fiscal Year 2024 Results on Mar 26, 2025 Mabpharm Limited announced that they will report fiscal year 2024 results on Mar 26, 2025 New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.0% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Jan 02
Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection) The board of directors of Mabpharm Limited announce that the registration of CMAB008 (infliximab for injection), a core product of the Company and a recombinant anti-tumor necrosis factor ("TNF ") human-mouse chimeric monoclonal antibody independently developed by the Company, was recently approved by the Drug Regulatory Authority of Pakistan for the treatment of: ulcerative colitis in adults; ankylosing spondylitis; rheumatoid arthritis; Crohn's disease in adults and pediatric patients aged above 6 years old; fistula Crohn's disease; and psoriasis. Generic name of the drug: infliximab for injection Dosage form: Injections Specification: 100mg/vial Drug manufacturer: Taizhou Mabtech Pharmaceutical Limited Drug approval number: 120570 (Pakistan) CMAB008 is the first infliximab developed in the People's Republic of China (the "PRC") and approved for marketing, which is a monoclonal antibody biosimilar independently developed by the Company and a core product of the Company. CMAB008 uses the Chinese hamster ovary cell expression system, and is a monoclonal antibody targeting TNF that specifically merges with TNF and blocks the inflammatory cascade response caused by TNF; it is mainly used for treatment of ulcerative colitis in adults, ankylosing spondylitis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, rheumatoid arthritis and psoriasis. The researches we have completed have shown that, compared to other anti-TNF drugs on the market, CMAB008 (infliximab for injection) has a stronger affinity for TNF and a stronger glycosylation character, with rapid onset of effect, long-lasting efficacy, long dosing intervals and no hypersensitivity reactions. The results of our completed researches including, clinical trials, non-clinical comparative studies, and pharmacological comparisons of CMAB008 have also shown that CMAB008 is identical to the original infliximab in terms of efficacy, safety, pharmacological profile and quality. Infliximab is included in the PRC's basic medical insurance program (the "Medical Insurance") drug catalogue, and in accordance with relevant regulations on Medical Insurance of the PRC, our CMAB008 is applicable to the Medical Insurance coverage of infliximab, thus providing a new and more economical and affordable option for patients. Reported Earnings • Sep 27
First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.024 loss in 1H 2023) First half 2024 results: CN¥0.024 loss per share (in line with 1H 2023). Revenue: CN¥108.5m (up 146% from 1H 2023). Net loss: CN¥97.6m (loss narrowed 2.4% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Aug 15
Mabpharm Limited to Report First Half, 2024 Results on Aug 28, 2024 Mabpharm Limited announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Jul 11
Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer The board of directors of Mabpharm Limited announced that Mr. Li Yunfeng (‘Mr. Li’) will no longer holds the position of chief financial officer of the Company with effect from July 10, 2024. Mr. Li Yunfeng, aged 47, and was appointed as an executive Director since July 20, 2018. He is primarily responsible for overseeing the management of market development, investment and legal work of Group. Mr. Li joined Group and served as a deputy general manager of Taizhou Pharmaceutical since March 2016, and was appointed as a director of Taizhou Pharmaceutical and Shengheng Biotechnology in August 2018 and November 2019, respectively. Mr. Li has over 20 years of experience in the biotechnology industry, which in the Directors' view, enables him to competently carry out responsibilities in Group. From January 2002 to June 2009, and from July 2010 to November 2012, Mr. Li was employed by Shanghai CP Guojian Pharmaceutical Co. Ltd. as a deputy general manager. Mr. Li worked as a deputy general manager at Shanghai National Engineering Research Center of Antibody Medicine Co. Ltd. from July 2009 to June 2010 and a general manager of Shanghai Lansheng Guojian Pharmaceutical Co. Ltd. from December 2012 to March 2016. Mr. Li served as a deputy general manager of Zhangjiang Biotechnology from March 2016 to July 2017. He also worked as a deputy general manager of Biomabs and MTJA respectively from March 2016 to August 2018. Mr. Li obtained a bachelor degree in international economics from Nanjing Normal University in July 1998. Announcement • Jul 10
Mabpharm Limited Announces Changes to Its Board The board of directors of Mabpharm Limited announced board changes. With effect from July 10, 2024, Mr. Cen Jialin (‘Mr. Cen’) and Dr. Tao Qian (‘Dr. Tao’) will be appointed as a non-executive Director and an independent non-executive Director respectively. Mr. Cen Jialin, aged 49, currently serves as an executive director of CDH Investments. From August 2002 to September 2004, Mr. Cen served as the manager of the operation and procurement department in Shenzhen branch of AEON (China) Co. Ltd. From January 2006 to April 2007, Mr. Cen served as the general manager in charge of the retail division in Chongqing branch and Maoming branch of CapitaLand China. From March 2007 to March 2018, Mr. Cen served as the general manager of Skycity Group. Mr. Cen has been an executive director of CDH Investments since April 2018. Mr. Cen obtained a bachelor's degree in finance and securities from Shenzhen University in July 1999 and obtained a master's degree in business administration from Washington University in St. Louis in December 2012. Dr. Tao Qian, aged 58, currently serves as a professor of department of clinical oncology at The Chinese University of Hong Kong. Dr. Tao is a leader in cancer epigenetics and tumor suppressor genes study in Asia and has published 189 journal articles and 5 book chapters with over 14,000 citations. Dr. Tao served as a research associate at Shantou University Medical College from 1988 to 1990 and a lecturer from 1990 to 1991 at the aforementioned university. Dr. Tao served as an assistant professor of department of oncology at Johns Hopkins School of Medicine from February 1999 to August 2004 and a consultant from August 2004 to November 2006 at the aforementioned university. Dr. Tao served as an adjunct associate professor of department of microbiology at the National University of Singapore from 2001 to 2004. Dr. Tao also served as an associate professor of department of clinical oncology at The Chinese University of Hong Kong from August 2004 to August 2008. Dr. Tao obtained a bachelor's degree in biology from Hunan Normal University in July 1985 and obtained a master degree in genetics from Xiamen University in August 1988. Dr. Tao was awarded a doctor of philosophy in molecular pathology and virology from The University of Hong Kong in November 1996 and has been a postdoctoral fellow at Sidney Kimmel Comprehensive Cancer Center from September 1995 to February 1999. The board announced that Dr. Qian Weizhu (‘Dr. Qian’), currently a non-executive Director of the Company, will be re-designated as an executive Director. Dr. Qian Weizhu, aged 48, was appointed as a non-executive director of the Company and a director of Taizhou Mabtech Pharmaceutical Limited and Shanghai Shengheng Biotechnology Limited in November 2023 and is responsible for participating in the formulation of the Group's business and corporate strategies. Dr. Qian has more than 25 years of experience in oncology and biology fields. Dr. Qian was employed at the Cancer Institute of Second Military Medical University from 1994 to 2013, primarily responsible for biotechnology research and development. Dr. Qian consecutively served as deputy general manager and general manager of Shanghai Zhangjiang Biotechnology Co. Ltd. from January 2014 to July 2017. Dr. Qian worked as a director and general manager in Shanghai Biomabs Pharmaceuticals Co. Ltd. (‘Biomabs’) from October 2015 to August 2018 and from December 2020 to October 2023, and as the vice president of Shanghai Mabstar Biotechnology Co. Ltd. from November 2023 to July 2024. Dr. Qian also served as general manager in Shanghai Sinomab Biotechnology Co. Ltd. (‘MTJA’) from February 2016 to August 2018. Dr. Qian was a legal representative of Shanghai Guojian Biotechnology Research Institute from February 2015 to September 2018. Dr. Qian joined Group in February 2015, and served consecutively as a director and chairman of the board of directors in Taizhou Pharmaceutical from February 2015 to October 2020, during which she had been deputy general manager and general manager of Taizhou Pharmaceutical consecutively from February 2015 to August 2018. Dr. Qian served as a director and general manager of Shengheng Biotech from August 2018 to October 2020. Dr. Qian served as the executive director and chief executive officer of the Company from July 2018 to October 2020 and served as a member of the nomination committee of the Company from the listing date of the Company (being May 31, 2019) to October 2020. Dr. Qian obtained a master's degree in biochemistry and molecular biology in June 2003 from Second Military Medical University and was awarded a doctorate degree in oncology in June 2011 from the aforementioned university. Announcement • Jul 03
Mabpharm Limited Announces Approval from the Ministry of Health of Peru on the New Drug Application of CMAB008 (Infliximab for Injection) The board of directors of Mabpharm Limited announced that the new drug application of CMAB008 Lei Ting® (infliximab for injection), a core product of the Company and a recombinant anti-tumor necrosis factora ("TNFa") human- mouse chimeric monoclonal antibody independently developed by the Company, was recently approved by the Ministry of Health of Peru (Ministerio de Salud) for the treatment of: (i) ulcerative colitis in adults; (ii) ankylosing spondylitis; (iii) rheumatoid arthritis; (iv) Crohn's disease in adults and pediatric patients aged above 6 years old; (v) fistula Crohn's disease; and (vi) psoriasis. CMAB008 is the first infliximab developed in the People's Republic of China (the "PRC") and approved for marketing, which is a monoclonal antibody biosimilar independently developed by the Company and a core product of the Company. CMAB008 uses the Chinese hamster ovary cell expression system, and is a monoclonal antibody targeting TNF that specifically merges with TNF and blocks the inflammatory cascade response caused by TNF; it is mainly used for treatment of ulcerative colitis in adults, ankylosing spondylitis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, rheumatoid arthritis and psoriasis. The researches they have completed have shown that, compared to other anti-TNF drugs on the market, CMAB008 (infliximab for injection) has a stronger affinity for TNF and a stronger glycosylation character, with rapid onset of effect, long-lasting efficacy, long dosing intervals and no hypersensitivity reactions. The results of completed researches including, clinical trials, non-clinical comparative studies, and pharmacological comparisons of CMAB008 have also shown that CMAB008 is identical to the original infliximab in terms of efficacy, safety, pharmacological profile and quality. The antibody drug production base of Taizhou Mabtech Pharmaceutical Limited under the Company in China Medical City, Taizhou, Jiangsu Province also successfully passed the good manufacturing practices ("GMP") compliance inspection for CMAB008 by Jiangsu Provincial Drug Administration. Infliximab is included in the PRC's basic medical insurance program (the "Medical Insurance") drug catalogue, and in accordance with relevant regulations on Medical Insurance of the PRC, CMAB008 is applicable to the Medical Insurance coverage of infliximab, thus providing a new and more economical and affordable option for patients. Announcement • Jun 26
Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA On June 25, 2024, Simcere Zaiming announced that Enlituo®? (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EGFR) antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration (NMPA) for marketing. Enlituo®? is indicated for use in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Enlituo® (cetuximab beta, originally known as CMAB009) is a recombinant EGFR monoclonal antibody developed independently in China. Classified as a 2.4 class modified biological new drug, cetuximab beta is prepared using a proprietary protein expression technique, effectively avoiding glycosylation modification that may lead to hypersensitivity. Enlituo® received approval based on robust evidence from a phase 2/3 study and a phase 3 confirmatory clinical trial. In an open-label, randomized, controlled, multicenter, prospective phase 3 study, 505 subjects with RAS/BRAF wild-type mCRC were treated and analyzed. Clinical data revealed that combining cetuximab beta with FOLFIRI significantly extended progression-free survival (PFS) compared to FOLFIRI alone (13.133 months vs. 9.567 months, P = 0.004). Additionally, the combination increased the objective response rate (ORR) (69.1% vs. 42.3%, P < 0.001) and overall survival (OS) (2.322 years vs. 1.900 years, P = 0.024). Enlituo represents the first EGFR monoclonal antibody drug developed in China with independent intellectual property rights that are approved for the first-line treatment of mCRC. The successful launch of Enlituo® will provide high quality and affordable biological targeted remedy for Chinese cancer patients. In March 2023, the drug marketing application of Enlituo® was accepted by the NMPA. On August 18, 2023, the Group entered into a cooperation agreement with Mabpharm, pursuant to which the Group obtained the exclusive commercial rights in respect of Enlituo® in Chinese mainland. Announcement • Mar 27
Mabpharm Limited, Annual General Meeting, Jun 21, 2024 Mabpharm Limited, Annual General Meeting, Jun 21, 2024. Reported Earnings • Mar 27
Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.051 loss in FY 2022) Full year 2023 results: CN¥0.05 loss per share (improved from CN¥0.051 loss in FY 2022). Revenue: CN¥87.2m (up 56% from FY 2022). Net loss: CN¥209.4m (flat on FY 2022). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Announcement • Mar 14
Mabpharm Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mabpharm Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 Announcement • Nov 29
Mabpharm Limited Announces Director Changes The board (the "Board") of directors of Mabpharm Limited announced the following changes in composition of the Board. RESIGNATION OF DIRECTORS: With effect from November 28, 2023, Mr. Guo Jianjun ("Mr. Guo") will resign as a non-executive Director due to age concern and Dr. Li Jing ("Dr. Li") will resign as an executive Director in order to devote more time to her other personal commitments. APPOINTMENT OF DIRECTORS: With effect from November 28, 2023, Dr. Hou Sheng ("Dr. Hou") and Dr. Qian Weizhu ("Dr. Qian") will be appointed as an executive Director and non-executive Director respectively. Dr. Hou Sheng, aged 46, has over 20 years of experience in oncology and biology fields. Dr. Hou served as an assistant researcher and associate researcher and was employed at translational medical research department on tumor cell biology of Second Military Medical University (currently known as People's Liberation Army Navy Medical University from May 2008 to March 2016. From May 2008 to August 2012, Dr. Hou served as an assistant researcher and associate researcher at National Engineering Research Center for Antibody Medicine. From September 2012 to February 2021, Dr. Hou served as a deputy director and associate researcher at State Key Laboratory of Antibody Drugs and Targeted Therapy. From April 2021 to July 2023, Dr. Hou was the chairman of the board of directors and general manager of Wuhan Guojian Baiao Pharmaceutical Co. Ltd. Dr. Hou is the spouse of Dr. Qian. Dr. Hou obtained his bachelor's degree in medicine from Second Military Medical University (currently known as People's Liberation Army Navy Medical University in June 2000, and was awarded his master's and doctorate degrees in oncology from the aforementioned university in June 2005. Dr. Hou received second prize in State Technological Invention Award in 2007, first prize in Shanghai Science and Technology Award two times in 2006 and 2011 respectively, and second prize in Shanghai Technology Invention Award. Dr. Qian Weizhu, aged 48, currently serves as the vice president of Shanghai Biomabs Pharmaceuticals Co. Ltd. ("Biomabs") and the consultant of the Company. Dr. Qian has more than 25 years of experience in oncology and biology fields. Dr. Qian was employed at the Cancer Institute of Second Military Medical University (currently known as People's Liberation Army Navy Medical University from 1994 to 2013, primarily responsible for biotechnology research and development. Dr. Qian consecutively served as deputy general manager and general manager of Shanghai Zhangjiang Biotechnology Co. Ltd. from January 2014 to July 2017. Dr. Qian worked as a director and general manager in Biomabs from October 2015 to August 2018 and from December 2020 to October 2023. Dr. Qian also served as general manager in Shanghai Sinomab Biotechnology Co. Ltd. from February 2016 to August 2018. Dr. Qian was a legal representative of Shanghai Guojian Biotechnology Research Institute from February 2015 to September 2018. Dr. Qian joined the Group in February 2015, and served consecutively as a director and chairman of the board of directors in Taizhou Mabtech Pharmaceutical Limited ("Taizhou Pharmaceutical") from February 2015 to October 2020, during which she had been deputy general manager and general manager of Taizhou Pharmaceutical consecutively from February 2015 to August 2018. Dr. Qian served as the executive director and chief executive officer of the Company from July 2018 to October 2020. Dr. Qian is the spouse of Dr. Hou. Dr. Qian obtained a master's degree in biochemistry and molecular biology in June 2003 from Second Military Medical University (currently known as People's Liberation Army Navy Medical University) and was awarded a doctorate degree in oncology in June 2011 from the aforementioned university. Reported Earnings • Aug 28
First half 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.028 loss in 1H 2022) First half 2023 results: CN¥0.024 loss per share (improved from CN¥0.028 loss in 1H 2022). Revenue: CN¥44.0m (up 53% from 1H 2022). Net loss: CN¥100.0m (loss narrowed 14% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Announcement • Aug 16
Mabpharm Limited to Report First Half, 2023 Results on Aug 25, 2023 Mabpharm Limited announced that they will report first half, 2023 results on Aug 25, 2023 Reported Earnings • Mar 26
Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.071 loss in FY 2021) Full year 2022 results: CN¥0.05 loss per share (improved from CN¥0.071 loss in FY 2021). Net loss: CN¥210.8m (loss narrowed 28% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Liangzhong Guo was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Aug 17
Mabpharm Limited to Report First Half, 2022 Results on Aug 26, 2022 Mabpharm Limited announced that they will report first half, 2022 results on Aug 26, 2022 Announcement • Jul 28
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis The board of directors of Mabpharm Limited announced that the National Medical Products Administration of China (the "NMPA") has approved the clinical trial application of CMAB015 for the treatment of psoriasis and ankylosing spondylitis. CMAB015 (Secukinumab) is a biosimilar candidate for secukinumab. It is expected that CMAB015 may be approved by the NMPA for marketing in the fourth quarter of 2025. CMAB015 targets interleukin 17A (IL-17A) for treating psoriasis and ankylosing spondylitis. Secukinumab is currently the most effective curer for psoriasis, which offers significant efficacy and guarantees a more stable condition after drug withdrawal compared with the peers. Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that the Group will beable to obtain approval, develop or ultimately market, CMAB015 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company. Announcement • Jul 06
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017 The board of directors of Mabpharm Limited announced that the National Medical Products Administration of China has approved the clinical trial application of biological class I new drug CMAB017 for the treatment of advanced solid tumors, including but not limited to colorectal cancer, head and neck squamous cell carcinomas and esophageal squamous cell carcinoma. CMAB017 (anti-EGFR probody) is an innovative probody drug. Results of the completed experimental study on tissue distribution of tumor-bearing mice show that CMAB017 concentrates locally in tumor 24-72 hours after administration. It expects to commence phase III clinical trial in the fourth quarter of 2024. It expects that CMAB017 may be approved by the NMPA for marketing in the fourth quarter of 2027. Regarding CMAB017, the design of blocking peptide is expected to significantly reduce adverse skin reactions, gastrointestinal mucosa, etc. The selection of IgG1 constant region can enhance the effect mediated by Fc fragment of antibody and thus improve the curative effect. CMAB017 is a biological class I new drug with better efficacy and safety than similar products available on the market, and it is expected that more new probody drugs will be developed by leveraging the research and development platform of CMAB017. CMAB017 is indicated for the treatment of advanced solid tumors, including but not limited to colorectal cancer, head and neck squamous cell carcinomas and esophageal squamous cell carcinoma. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Liangzhong Guo was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Jan 14
Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China Mabpharm Limited announced that the National Medical Products Administration of China has approved the clinical trial application of CMAB807X for treatment of tumor bone metastasis.CMAB807X (Denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand), which is a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. CMAB807 prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bones. CMAB807 is currently under phase III clinical trials for osteoporosis. CMAB807X is a dosage form of CMAB807 for the treatment of tumor bone metastasis. It is expected that CMAB807X can be used for treatment of tumor bone metastasis and giant bone cell tumor and prevent skeletal-related events in patients with solid tumor bone metastases and multiple myeloma after its new drug application is approved by the NMPA. Reported Earnings • Aug 31
First half 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.013 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: CN¥81.2m (up CN¥68.5m from 1H 2020). Net loss: CN¥145.2m (loss widened 168% from 1H 2020). Announcement • Mar 17
Mabpharm Limited to Report Fiscal Year 2020 Results on Mar 26, 2021 Mabpharm Limited announced that they will report fiscal year 2020 results on Mar 26, 2021 Is New 90 Day High Low • Mar 10
New 90-day high: HK$1.18 The company is up 1.0% from its price of HK$1.17 on 10 December 2020. The Hong Kong market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 24% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: HK$1.08 The company is down 8.0% from its price of HK$1.18 on 29 September 2020. The Hong Kong market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period. Is New 90 Day High Low • Nov 02
New 90-day low: HK$1.14 The company is down 7.0% from its price of HK$1.22 on 04 August 2020. The Hong Kong market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 10.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: HK$1.15 The company is down 16% from its price of HK$1.37 on 26 June 2020. The Hong Kong market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Announcement • Aug 31
Mabpharm Limited to Report First Half, 2020 Results on Aug 26, 2020 Mabpharm Limited announced that they will report first half, 2020 results on Aug 26, 2020